Fibromyalgia (FM) is a multisystem disorder frequently associated with functional gastrointestinal disorders, particularly irritable bowel syndrome (IBS). Diet-related factors and gut microbiota alterations, key elements in IBS pathophysiology, may disrupt the gut-brain axis, promoting immune activation, altered pain processing, and peripheral nerve dysfunction, including small fibre involvement, which has been consistently reported in FM. The study investigated whether IBS symptom severity in FM is associated with clinical and psychological features and with neuropathological evidence of small fibre involvement. In this monocentric cross-sectional observational study, 89 FM patients underwent clinical and psychological assessments. IBS severity was assessed using the IBS Severity Scoring System (IBS-SSS). Skin biopsy with quantification of intraepidermal nerve fibre density (IENFD) at proximal and distal sites was performed in 57 patients. Patients were classified into mild-moderate and severe IBS groups. Between-group differences were analysed using Mann-Whitney U and χ² tests. Spearman's rank correlation served to assess associations between IBS severity, clinical variables, and IENFD. Severe IBS symptoms were present in 47.1% of patients. Compared with patients with mild-moderate IBS, those with severe IBS showed higher widespread pain index (WPI) and symptom severity scale (SSS) scores, indicating greater fibromyalgia severity, as well as increased anxiety and depressive symptoms, reduced sleep duration, and greater functional impairment (all p<0.05 after FDR correction). Skin biopsy revealed a higher prevalence of reduced IENFD, particularly at proximal sites, in severe IBS patients. Notably, IBS-SSS scores were negatively correlated with proximal IENFD (r=-0.34, p=0.01). IBS severity identifies a clinically more severe FM phenotype with small fibre pathology. These findings are consistent with a possible interaction between gastrointestinal dysfunction and peripheral nerve involvement in FM, although mechanistic pathways require further investigation.
Galcanezumab is a well-tolerated monoclonal antibody developed for migraine prophylaxis. Although its action mechanisms are not fully understood, they may involve changes in cortical connectivity. This study explores galcanezumab-induced central changes by investigating metabolic-electrical brain interactions and network properties. We analyzed electroencephalography (EEG) and functional near-infrared spectroscopy (fNIRS) during visual stimulation through connectivity and high-order interaction analyses using Partial information decomposition (PID). Furthermore, we explored the relationship between neurophysiological measures and long-term clinical effects. Fifteen patients underwent clinical and EEG/fNIRS recordings at baseline (B), 1 hour after the first galcanezumab administration (B’), and after 3 months of therapy (3M). Clinical outcomes were assessed after one year of treatment (1Y). Ten healthy controls underwent baseline EEG/fNIRS recordings. EEG and fNIRS signals were analyzed and harmonized. We computed global network properties including strength, global efficiency, clustering coefficient, and high-order interaction properties such as synergy and redundancy. For both EEG and fNIRS data, we found lower strength and clustering coefficients in patients than in controls at all time points \((p<0.05)\). Global efficiency was reduced at B, and significantly increased in patients at 3M, reaching levels comparable to controls. PID on fNIRS data showed an overall increase in redundancy and synergy after treatment \((p<0.05)\). Cluster analysis on EEG and fNIRS synergy matrices over time showed expansion of high-synergy channel clusters at 3M. Finally, for both EEG and fNIRS data, synergy and global efficiency at 3M correlated with clinical indicators at 1Y, including migraine-related disability and the number of acute medications/month \((p<0.05)\). The results support central effects of galcanezumab associated with increased integration in functional and electrical brain connectivity, explaining its long-term efficacy and disease-modifying action.
Background: Essential tremor (ET) is a clinically heterogeneous disorder involving motor and non-motor features. Voluntary movement abnormalities, including movement slowness (bradykinesia), have been frequently described in ET. Among non-motor symptoms, insomnia is also frequently reported, raising the possibility of shared underlying mechanisms with bradykinesia (e.g., brainstem noradrenergic dysfunction involving the locus coeruleus due to Lewy body pathology). We investigated the relationship between movement abnormalities, as objectively quantified using finger-tapping kinematic analysis, and sleep disturbances in ET. Methods: A subsample of 29 ET patients included in a previous study underwent kinematic analysis of finger-tapping. Insomnia was evaluated using the Insomnia Severity Index (ISI). Patients were stratified according to the presence of bradykinesia (e.g, movement slowness during finger-tapping) and insomnia (ISI ≥ 8). Group comparisons and correlational analyses were performed to assess the association between kinematic measures of bradykinesia, insomnia severity and other clinical features. Results: Fourteen subjects (48.3%) exhibited bradykinesia on kinematic analysis, and eleven patients (37.9%) met the criteria for insomnia. The prevalence of insomnia was similar between patients with and without bradykinesia. Likewise, no significant differences in finger-tapping kinematics were observed between ET patients with and without insomnia. Kinematic measures of bradykinesia did not correlate with ISI scores (all p > 0.05), whereas ISI scores were significantly positively correlated with clinical tremor severity. Conclusions: The current kinematic analysis suggests no relationship between movement abnormalities and sleep disturbances in ET. While bradykinesia in ET possibly relies on the dysfunction of cerebellar–basal ganglia circuits, insomnia in ET may reflect prominent brainstem dysfunction. Larger studies integrating kinematic assessments, neuroimaging, and longitudinal designs are needed to clarify the relationship between movement and sleep disturbances in ET